Skip to main content

Table 1 Prevalence of anti-MAP Abs and MAP DNA among CD, UC and nIBD patients

From: Mycobacterium avium subsp. paratuberculosis and associated risk factors for inflammatory bowel disease in Iranian patients

Diagnosis anti-MAP1
Abs+
anti-MAP1
Abs−
anti-MAP2
Abs+
anti-MAP2
Abs−
IS900+ IS900−
CD 13 (46%) 15 (54%) 11 (39%) 17 (61%) 18 (64%) 10 (36%)
UC 1 (3%) 29 (97%) 5 (16.7%) 25 (83.3%) 10 (33%) 20 (67%)
nIBD 3 (5%) 59 (95%) 4 (6%) 58 (94%) 7 (9.7%) 55 (90.3%)
  1. Numbers with the relative percentages of subjects positive (Abs+) and negative (Abs−) to MAP3865c133–141 (MAP1) and MAP3865c125–133 (MAP2) peptides. Analogous data referred to detection of MAP-specific IS900 gene is provided for each group